ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, will announce its interim results for the six months ended 30 September 2019 on Friday 6 December 2019.
A meeting for analysts will be held at 09.30am on the morning of the results at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.
To access a webcast of the analyst presentation, please log on to the following web address approximately 10 minutes before 09.30am on the day of the results:
A recording of the presentation will be made available on ReNeuron's website, www.reneuron.com.
+44 (0) 20 3819 8400
Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan (UK Media/Investor Relations)
+44 (0) 20 7466 5000
Mark Court, Tilly Abraham
Argot Partners (US Media/Investor Relations)
Claudia Styslinger, David Rosen
+1 212 600 1902
Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)
Jonathan Senior, Stewart Wallace, Ben Maddison
+44 (0) 20 7710 7600
N+1 Singer (Joint Broker)
Aubrey Powell, James Moat, Mia Gardner
+44 (0) 20 7496 3000
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
ReNeuron Group PLC's (LON:RENE) Michael Hunt caught up with Proactive London's Andrew Scott soon after the release of its interim results to September 2019.
The biotech firm says it's in ongoing discussions with “commercial third parties” interested in out-licence deals across all its...